TLP-0001 is under clinical development by Tella and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TLP-0001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLP-0001 is under development for the treatment of pancreatic cancer and wet age-related macular degeneration. It is administered through intradermal and subcutaneous route. It is a WT1 peptide-pulsed dendritic cell vaccine. Peptide-pulsed dendritic cell vaccine is consisting of autologous dendritic cells which have been pulsed with a peptide. It was also under development for the treatment of esophageal cancer, advanced malignant melanoma and biliary tumors.
tella is a drug development company. It offers vaccines for cancer treatment. The company offers dendritic cell vaccine therapy which develops dendritic cells to convey the information on cancer markers to lymphocytes and increase the dendritic cell population and strengthen the attacking system against cancers. It also develops cell medicine and regenerative medicine for cancer. Tella provides operational support and consultation services. The company offers its therapy for contracted medical institutions in Japan. Tella is headquartered in Tokyo, Japan
For a complete picture of TLP-0001’s drug-specific PTSR and LoA scores, buy the report here.